{"seq": 1, "ts": "2026-02-20T10:25:13.340530+00:00", "agent": "agent3", "cmd": "pm --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm - PubMed CLI tools for AI agents\n\nUsage: pm <command> [OPTIONS]\n\nCommands:\n  init        Initialize audit trail and cache (.pm/)\n  search      Search PubMed, return PMIDs\n  fetch       Fetch PubMed XML by PMIDs\n  parse       Parse PubMed XML to JSONL\n  filter      Filter JSONL articles by field patterns\n  cite        Fetch CSL-JSON citations\n  download    Download full-text PDFs\n  diff        Compare two JSONL files by PMID\n  audit       View audit trail and PRISMA report\n  quick       One-command search pipeline (outputs JSONL)\n\nExamples:\n  pm search \"CRISPR cancer\" | pm fetch | pm parse > results.jsonl\n  pm quick \"covid vaccine\" --max 50\n  pm filter --year 2024 --has-abstract < articles.jsonl\n\nUse 'pm <command> --help' for command-specific help.\n", "stderr": ""}
{"seq": 2, "ts": "2026-02-20T10:25:20.624189+00:00", "agent": "agent3", "cmd": "pm search --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm search - Search PubMed and return PMIDs\n\nUsage: pm search [OPTIONS] \"search query\"\n\nOptions:\n  --max N        Maximum results to return (default: 10000)\n  --refresh      Bypass cache and re-fetch from PubMed\n  -h, --help     Show this help message\n\nOutput:\n  PMIDs to stdout, one per line\n\nExamples:\n  pm search \"CRISPR cancer therapy\"\n  pm search --max 100 \"machine learning\"\n  pm search \"covid vaccine 2024\" | pm fetch | pm parse > results.jsonl\n\nQuery syntax:\n  Uses PubMed query syntax. See:\n  https://pubmed.ncbi.nlm.nih.gov/help/#search-tags\n", "stderr": ""}
{"seq": 3, "ts": "2026-02-20T10:25:27.770644+00:00", "agent": "agent3", "cmd": "pm fetch --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm fetch - Fetch PubMed XML from E-utilities API\n\nUsage: echo \"12345\" | pm fetch > articles.xml\n       cat pmids.txt | pm fetch > articles.xml\n\nOptions:\n  -v, --verbose  Show progress on stderr\n  -h, --help     Show this help message\n\nInput:\n  PMIDs from stdin, one per line\n\nOutput:\n  PubMed XML to stdout\n\nFeatures:\n  - Batches requests (200 PMIDs per API call)\n  - Rate limits to ~3 requests/second\n  - Exits with error on network failure\n\nExamples:\n  echo \"12345\" | pm fetch > article.xml\n  cat pmids.txt | pm fetch > articles.xml\n  pm search \"CRISPR\" | pm fetch | pm parse > results.jsonl\n", "stderr": ""}
{"seq": 4, "ts": "2026-02-20T10:25:34.317705+00:00", "agent": "agent3", "cmd": "pm parse --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm parse - Parse PubMed XML to JSONL\n\nUsage: cat articles.xml | pm parse [OPTIONS] > articles.jsonl\n       zcat articles.xml.gz | pm parse [OPTIONS] > articles.jsonl\n\nOptions:\n  -v, --verbose  Show progress on stderr\n  -h, --help     Show this help message\n\nOutput:\n  One JSON object per line (JSONL format) with fields:\n    pmid, title, authors, journal, year, date, doi, pmcid, abstract\n\nExamples:\n  cat pubmed.xml | pm parse > articles.jsonl\n  zcat pubmed25n0001.xml.gz | pm parse > articles.jsonl\n  cat pubmed.xml | pm parse --verbose > articles.jsonl 2>progress.log\n", "stderr": ""}
{"seq": 5, "ts": "2026-02-20T10:25:40.802839+00:00", "agent": "agent3", "cmd": "pm filter --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm filter - Filter JSONL articles by field patterns\n\nUsage: pm parse | pm filter [OPTIONS]\n       cat articles.jsonl | pm filter [OPTIONS]\n\nFilter Options:\n  --year PATTERN      Year filter (exact, range, or open-ended)\n                      Examples: 2024, 2020-2024, 2020-, -2024\n  --journal PATTERN   Journal contains PATTERN (case-insensitive)\n  --journal-exact STR Journal equals STR exactly\n  --author PATTERN    Any author contains PATTERN (case-insensitive)\n  --has-abstract      Article has non-empty abstract\n  --has-doi           Article has DOI\n\nGeneral Options:\n  -v, --verbose       Show filter stats on stderr\n  -h, --help          Show this help\n\nExamples:\n  pm filter --year 2020- --journal nature --has-abstract\n  pm filter --author smith\n  pm filter --year 2020-2024\n\nNotes:\n  - Multiple filters combine with AND logic\n  - Malformed JSON lines are silently skipped\n", "stderr": ""}
{"seq": 6, "ts": "2026-02-20T10:25:48.343921+00:00", "agent": "agent3", "cmd": "pm search Lu-PSMA dosimetry prostate cancer --max 100", "exit_code": 0, "stdin_lines": 0, "stdout": "41713513\n41653847\n41635157\n41595153\n41543663\n41529924\n41506803\n41448174\n41342316\n41203980\n41185988\n41067860\n41044003\n41043997\n41043996\n41003914\n40985608\n40968399\n40903914\n40876952\n40831923\n40774698\n40723196\n40665456\n40649754\n40638023\n40591184\n40591108\n40586937\n40582602\n40403928\n40397137\n40395199\n40393564\n40393125\n40345822\n40111714\n40111669\n40063298\n39935268\n39894880\n39875849\n39753366\n39704811\n39623240\n39570450\n39404984\n39355047\n39335092\n39310108\n39302840\n39211146\n39131436\n39093035\n39017988\n38960712\n38901967\n38820867\n38724653\n38724282\n38646643\n38568428\n38534939\n38505615\n38423787\n38287346\n38164586\n38145595\n38069337\n38050121\n37982573\n37934033\n37891072\n37864592\n37829345\n37770108\n37743194\n37695374\n37652546\n37652541\n37620052\n37565281\n37442604\n37323189\n37119703\n37116918\n37111725\n37000000\n36924989\n36838872\n36760133\n36757516\n36741017\n36692682\n36657980\n36629878\n36597884\n36583623\n36284803\n36182983\n", "stderr": ""}
{"seq": 7, "ts": "2026-02-20T10:25:57.200677+00:00", "agent": "agent3", "cmd": "pm fetch -v", "exit_code": 0, "stdin_lines": 0, "stdout": "", "stderr": ""}
{"seq": 8, "ts": "2026-02-20T10:26:04.737195+00:00", "agent": "agent3", "cmd": "pm init", "exit_code": 0, "stdin_lines": 0, "stdout": "Initialized .pm/ in /home/user/pm-tools/e2e/workdirs/agent3\nAudit trail: .pm/audit.jsonl\nCache: .pm/cache/\n", "stderr": ""}
{"seq": 11, "ts": "2026-02-20T10:26:12.210449+00:00", "agent": "agent3", "cmd": "pm parse -v 2", "exit_code": 0, "stdin_lines": 0, "stdout": "", "stderr": ""}
{"seq": 10, "ts": "2026-02-20T10:26:12.209517+00:00", "agent": "agent3", "cmd": "pm search Lu-PSMA dosimetry prostate cancer --max 100", "exit_code": 0, "stdin_lines": 0, "stdout": "41713513\n41653847\n41635157\n41595153\n41543663\n41529924\n41506803\n41448174\n41342316\n41203980\n41185988\n41067860\n41044003\n41043997\n41043996\n41003914\n40985608\n40968399\n40903914\n40876952\n40831923\n40774698\n40723196\n40665456\n40649754\n40638023\n40591184\n40591108\n40586937\n40582602\n40403928\n40397137\n40395199\n40393564\n40393125\n40345822\n40111714\n40111669\n40063298\n39935268\n39894880\n39875849\n39753366\n39704811\n39623240\n39570450\n39404984\n39355047\n39335092\n39310108\n39302840\n39211146\n39131436\n39093035\n39017988\n38960712\n38901967\n38820867\n38724653\n38724282\n38646643\n38568428\n38534939\n38505615\n38423787\n38287346\n38164586\n38145595\n38069337\n38050121\n37982573\n37934033\n37891072\n37864592\n37829345\n37770108\n37743194\n37695374\n37652546\n37652541\n37620052\n37565281\n37442604\n37323189\n37119703\n37116918\n37111725\n37000000\n36924989\n36838872\n36760133\n36757516\n36741017\n36692682\n36657980\n36629878\n36597884\n36583623\n36284803\n36182983\n", "stderr": ""}
{"seq": 9, "ts": "2026-02-20T10:26:12.191742+00:00", "agent": "agent3", "cmd": "pm fetch -v 2", "exit_code": 0, "stdin_lines": 100, "stdout": "<?xml version=\"1.0\" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2024//EN\"\n \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd\">\n<PubmedArticleSet>\n<PubmedArticle><MedlineCitation Status=\"Publisher\" Owner=\"NLM\"><PMID Version=\"1\">41713513</PMID><DateRevised><Year>2026</Year><Month>02</Month><Day>19</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1879-355X</ISSN><JournalIssue CitedMedium=\"Internet\"><PubDate><Year>2026</Year><Month>Feb</Month><Day>17</Day></PubDate></JournalIssue><Title>International journal of radiation oncology, biology, physics</Title><ISOAbbreviation>Int J Radiat Oncol Biol Phys</ISOAbbreviation></Journal><ArticleTitle>Continuous, Preclinical Activity Reconstruction in <sup>177</sup>Lu-based Radiopharmaceutical Therapy Using a Sparse Uncollimated \u03b3-Sensor Network.</ArticleTitle><ELocationID EIdType=\"pii\" ValidYN=\"Y\">S0360-3016(26)00403-7</ELocationID><ELocationID EIdType=\"doi\" ValidYN\n... [2241112 chars total, truncated] ...\nticleId><ArticleId IdType=\"pubmed\">28408527</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima S, Cuttler JM, Shimura N, Koga H, Murata A, Kawashima A. Present and future prospects of radiation therapy using \u03b1-emitting nuclides. Dose Response A Publ Int Hormesis Soc. 2018;16(1):1559325817747387.</Citation><ArticleIdList><ArticleId IdType=\"pmc\">PMC5784465</ArticleId><ArticleId IdType=\"pubmed\">29383010</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F. An overview of targeted alpha therapy with (225) actinium and (213) bismuth. Curr Radiopharm. 2018;11(3):200\u2013208. doi: 10.2174/1874471011666180502104524.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.2174/1874471011666180502104524</ArticleId><ArticleId IdType=\"pmc\">PMC6237921</ArticleId><ArticleId IdType=\"pubmed\">29732998</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>\n</PubmedArticleSet>", "stderr": "Fetching batch 1 (100 PMIDs)...\n"}
{"seq": 12, "ts": "2026-02-20T10:27:14.550961+00:00", "agent": "agent3", "cmd": "pm --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm - PubMed CLI tools for AI agents\n\nUsage: pm <command> [OPTIONS]\n\nCommands:\n  init        Initialize audit trail and cache (.pm/)\n  search      Search PubMed, return PMIDs\n  fetch       Fetch PubMed XML by PMIDs\n  parse       Parse PubMed XML to JSONL\n  filter      Filter JSONL articles by field patterns\n  cite        Fetch CSL-JSON citations\n  download    Download full-text PDFs\n  diff        Compare two JSONL files by PMID\n  audit       View audit trail and PRISMA report\n  quick       One-command search pipeline (outputs JSONL)\n\nExamples:\n  pm search \"CRISPR cancer\" | pm fetch | pm parse > results.jsonl\n  pm quick \"covid vaccine\" --max 50\n  pm filter --year 2024 --has-abstract < articles.jsonl\n\nUse 'pm <command> --help' for command-specific help.\n", "stderr": ""}
{"seq": 13, "ts": "2026-02-20T10:27:22.131347+00:00", "agent": "agent3", "cmd": "pm init", "exit_code": 1, "stdin_lines": 0, "stdout": "", "stderr": "Error: .pm/ already exists in /home/user/pm-tools/e2e/workdirs/agent3\n"}
{"seq": 14, "ts": "2026-02-20T10:27:28.484127+00:00", "agent": "agent3", "cmd": "pm search --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm search - Search PubMed and return PMIDs\n\nUsage: pm search [OPTIONS] \"search query\"\n\nOptions:\n  --max N        Maximum results to return (default: 10000)\n  --refresh      Bypass cache and re-fetch from PubMed\n  -h, --help     Show this help message\n\nOutput:\n  PMIDs to stdout, one per line\n\nExamples:\n  pm search \"CRISPR cancer therapy\"\n  pm search --max 100 \"machine learning\"\n  pm search \"covid vaccine 2024\" | pm fetch | pm parse > results.jsonl\n\nQuery syntax:\n  Uses PubMed query syntax. See:\n  https://pubmed.ncbi.nlm.nih.gov/help/#search-tags\n", "stderr": ""}
{"seq": 15, "ts": "2026-02-20T10:27:36.504392+00:00", "agent": "agent3", "cmd": "pm search Lu-177 PSMA dosimetry prostate cancer --max 100", "exit_code": 0, "stdin_lines": 0, "stdout": "41635157\n41613555\n41595153\n41543663\n41448174\n41280561\n41220111\n41203980\n41185988\n41067860\n41044003\n41043996\n41006727\n40985608\n40968399\n40903914\n40876952\n40839961\n40774698\n40649754\n40638023\n40591184\n40582602\n40434013\n40403928\n40397137\n40393564\n40345822\n40325261\n40306965\n40111714\n40063298\n39935268\n39894880\n39891713\n39875849\n39629134\n39355047\n39335092\n39310108\n39302840\n39142831\n39093035\n39062085\n38960712\n38901967\n38820867\n38679550\n38658392\n38646643\n38568428\n38534939\n38407630\n38372952\n38145595\n37982573\n37829345\n37645427\n37477566\n37323189\n37111725\n36838872\n36741017\n36692682\n36629878\n36597884\n36305305\n36182983\n35556158\n35456554\n35284969\n35045551\n34932154\n34893320\n34714082\n34418726\n34402687\n33921956\n33883176\n33709253\n33579037\n33443072\n33172774\n33092940\n32949253\n32859704\n32486054\n32391816\n32379495\n31806772\n31440799\n31414241\n31399803\n31321650\n30754620\n30534027\n30389816\n30291192\n30251544\n30076556\n", "stderr": ""}
{"seq": 17, "ts": "2026-02-20T10:27:44.045598+00:00", "agent": "agent3", "cmd": "pm search Lu-177 PSMA dosimetry prostate cancer --max 100", "exit_code": 0, "stdin_lines": 0, "stdout": "41635157\n41613555\n41595153\n41543663\n41448174\n41280561\n41220111\n41203980\n41185988\n41067860\n41044003\n41043996\n41006727\n40985608\n40968399\n40903914\n40876952\n40839961\n40774698\n40649754\n40638023\n40591184\n40582602\n40434013\n40403928\n40397137\n40393564\n40345822\n40325261\n40306965\n40111714\n40063298\n39935268\n39894880\n39891713\n39875849\n39629134\n39355047\n39335092\n39310108\n39302840\n39142831\n39093035\n39062085\n38960712\n38901967\n38820867\n38679550\n38658392\n38646643\n38568428\n38534939\n38407630\n38372952\n38145595\n37982573\n37829345\n37645427\n37477566\n37323189\n37111725\n36838872\n36741017\n36692682\n36629878\n36597884\n36305305\n36182983\n35556158\n35456554\n35284969\n35045551\n34932154\n34893320\n34714082\n34418726\n34402687\n33921956\n33883176\n33709253\n33579037\n33443072\n33172774\n33092940\n32949253\n32859704\n32486054\n32391816\n32379495\n31806772\n31440799\n31414241\n31399803\n31321650\n30754620\n30534027\n30389816\n30291192\n30251544\n30076556\n", "stderr": "pm: using cached search from 2026-02-20. Use --refresh to update.\n"}
{"seq": 16, "ts": "2026-02-20T10:27:44.045024+00:00", "agent": "agent3", "cmd": "pm fetch", "exit_code": 0, "stdin_lines": 100, "stdout": "<?xml version=\"1.0\" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2024//EN\"\n \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd\">\n<PubmedArticleSet>\n<PubmedArticle><MedlineCitation Status=\"PubMed-not-MEDLINE\" Owner=\"NLM\"><PMID Version=\"1\">41635157</PMID><DateCompleted><Year>2026</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2026</Year><Month>02</Month><Day>07</Day></DateRevised><Article PubModel=\"Print\"><Journal><ISSN IssnType=\"Print\">2146-1414</ISSN><JournalIssue CitedMedium=\"Print\"><Volume>35</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Feb</Month><Day>03</Day></PubDate></JournalIssue><Title>Molecular imaging and radionuclide therapy</Title><ISOAbbreviation>Mol Imaging Radionucl Ther</ISOAbbreviation></Journal><ArticleTitle>First Southeast Asian Experience of Terbium-161 PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Quantitative Imaging and Dosimetric Approach.</ArticleTitle><Pagin\n... [2494448 chars total, truncated] ...\nion>Bolch WE, et al. MIRD pamphlet no, 17: the dosimetry of nonuniform activity distributions--radionuclide S values at the voxel level. J Nucl Med. 1999;40(1):S11.</Citation><ArticleIdList><ArticleId IdType=\"pubmed\">9935083</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimes J, Celler A. Comparison of internal dose estimates obtained using organ-level, voxel S value, and Monte Carlo techniques. Med Phys. 2014;41(9):092501. doi: 10.1118/1.4892606.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1118/1.4892606</ArticleId><ArticleId IdType=\"pubmed\">25186410</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensel J, Thalmann GN. Biology of bone metastases in prostate cancer. Urology. 2016;92:6\u201313. doi: 10.1016/j.urology.2015.12.039.</Citation><ArticleIdList><ArticleId IdType=\"doi\">10.1016/j.urology.2015.12.039</ArticleId><ArticleId IdType=\"pubmed\">26768714</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>\n</PubmedArticleSet>", "stderr": ""}
{"seq": 18, "ts": "2026-02-20T10:27:52.604575+00:00", "agent": "agent3", "cmd": "pm parse", "exit_code": 0, "stdin_lines": 1982, "stdout": "{\"pmid\": \"41635157\", \"title\": \"First Southeast Asian Experience of Terbium-161 PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Quantitative Imaging and Dosimetric Approach.\", \"authors\": [\"Amnuaywattakorn Sasithorn\", \"Charoenphun Putthiporn\", \"Ativitavas Touch\", \"Pasawang Panya\", \"Khamwan Kitiwat\", \"Thongpraparn Thonnapong\", \"Khiewvan Benjapa\", \"Ruangma Ponkittiya\", \"Chamroonrat Wichana\", \"Chuamsaamarkkee Krisanat\"], \"journal\": \"Molecular imaging and radionuclide therapy\", \"year\": \"2026\", \"date\": \"2026-02-03\", \"abstract\": \"Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy has become an established treatment option for metastatic castration-resistant prostate cancer. Although lutetium-177 (177Lu) PSMA therapy has shown promising clinical benefits, terbium-161 (161Tb) PSMA is an emerging theranostic agent offering potential advantages due to its combination of beta and Auger electron emissions. This work presents the first documented case in\n... [340015 chars total, truncated] ...\nne WB-P image acquired either 24, 48, or 72\u00a0h post-injection (HP24, HP48, HP72). Total BM absorbed doses were determined as a sum of ROB, blood, major organ, and tumour contributions.\"}, {\"label\": \"RESULTS\", \"text\": \"Compared with the RP and for Lu-177-Octreotate therapy, median differences of the total BM absorbed doses were 13% (9-17%), 8% (4-15%), and 1% (0-5%) for the HP24, HP48, and HP72, respectively. For Lu-177-PSMA-617 therapy, total BM absorbed doses deviated 10% (2-20%), 3% (0-6%), and 2% (0-6%).\"}, {\"label\": \"CONCLUSION\", \"text\": \"For both Lu-177-Octreotate and Lu-177-PSMA-617 therapy, BM dosimetry via sequential QSPECT imaging and a single WB-P acquisition is feasible, if this WB-P image is acquired at a late time point (48 or 72\u00a0h post-injection). The reliability of the HP can be well accepted considering the uncertainties of quantitative Lu-177 imaging and BM dosimetry using standardised organ-level S values.\"}], \"pmcid\": \"PMC6081875\", \"doi\": \"10.1186/s13550-018-0427-z\"}\n", "stderr": ""}
{"seq": 19, "ts": "2026-02-20T10:28:43.574535+00:00", "agent": "agent3", "cmd": "pm filter --year 2025", "exit_code": 0, "stdin_lines": 100, "stdout": "{\"pmid\": \"41613555\", \"title\": \"161Tb-PSMA radioligand therapy in prostate cancer: current evidence and future perspectives.\", \"authors\": [\"Xiao Liming\", \"Zhao Ziyi\", \"Luo Rui\", \"Liu Fucen\", \"Hu Bosen\", \"Zhao Peng\", \"Yang Xia\", \"Chen Zhengguo\"], \"journal\": \"Frontiers in oncology\", \"year\": \"2025\", \"date\": \"2025\", \"abstract\": \"Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein, is overexpressed on the membranes of prostate cancer cells. Lutetium-177 (177Lu)- labelled PSMA-targeted radioligand therapy (PRLT) is employed in treating metastatic castration-resistant prostate cancer (mCRPC) that no longer responds to conventional therapies. However, some patients develop resistance or exhibit limited responsiveness, resulting in disease progression. Terbium-161 (161Tb) shares physical properties with 177Lu, as both isotopes emit \u03b2- particles. Notably, 161Tb also emits internal conversion and Auger electrons, offering potential advantages in the effective targeting \n... [116427 chars total, truncated] ...\nrieved and assessed for eligibility.\"}, {\"label\": \"RESULTS\", \"text\": \"A total of five studies were included in this systematic review (two prospective studies and three retrospective studies). The sample sizes of the studies ranged from 6 to 73 patients. The highest number of lesions analysed was 144. Three studies reported the SPECT/CT-SUV following cycle 1, and only one study reported the correlation with pretherapy PET/CT (r\u2009=\u20090.9, p\u2009=\u20090.005). SPECT/CT-SUV changes between the first two to three cycles were reported in one study. None of the studies reported the SPECT/CT-SUV for normal organs. One study reported correlations between SPECT/CT-derived SUV and PET/CT-derived SUV in target and nontarget tissues.\"}, {\"label\": \"CONCLUSION\", \"text\": \"Quantitative SPECT/CT-SUV can be used to predict responses to subsequent PSMA-TRT cycles. Disease burden and tumour heterogeneity are the leading causes of TRT individualisation.\"}], \"pmcid\": \"PMC11776189\", \"doi\": \"10.1186/s12880-025-01571-x\"}\n", "stderr": ""}
{"seq": 20, "ts": "2026-02-20T10:28:50.388356+00:00", "agent": "agent3", "cmd": "pm filter --has-abstract", "exit_code": 0, "stdin_lines": 100, "stdout": "{\"pmid\": \"41635157\", \"title\": \"First Southeast Asian Experience of Terbium-161 PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Quantitative Imaging and Dosimetric Approach.\", \"authors\": [\"Amnuaywattakorn Sasithorn\", \"Charoenphun Putthiporn\", \"Ativitavas Touch\", \"Pasawang Panya\", \"Khamwan Kitiwat\", \"Thongpraparn Thonnapong\", \"Khiewvan Benjapa\", \"Ruangma Ponkittiya\", \"Chamroonrat Wichana\", \"Chuamsaamarkkee Krisanat\"], \"journal\": \"Molecular imaging and radionuclide therapy\", \"year\": \"2026\", \"date\": \"2026-02-03\", \"abstract\": \"Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy has become an established treatment option for metastatic castration-resistant prostate cancer. Although lutetium-177 (177Lu) PSMA therapy has shown promising clinical benefits, terbium-161 (161Tb) PSMA is an emerging theranostic agent offering potential advantages due to its combination of beta and Auger electron emissions. This work presents the first documented case in\n... [340015 chars total, truncated] ...\nne WB-P image acquired either 24, 48, or 72\u00a0h post-injection (HP24, HP48, HP72). Total BM absorbed doses were determined as a sum of ROB, blood, major organ, and tumour contributions.\"}, {\"label\": \"RESULTS\", \"text\": \"Compared with the RP and for Lu-177-Octreotate therapy, median differences of the total BM absorbed doses were 13% (9-17%), 8% (4-15%), and 1% (0-5%) for the HP24, HP48, and HP72, respectively. For Lu-177-PSMA-617 therapy, total BM absorbed doses deviated 10% (2-20%), 3% (0-6%), and 2% (0-6%).\"}, {\"label\": \"CONCLUSION\", \"text\": \"For both Lu-177-Octreotate and Lu-177-PSMA-617 therapy, BM dosimetry via sequential QSPECT imaging and a single WB-P acquisition is feasible, if this WB-P image is acquired at a late time point (48 or 72\u00a0h post-injection). The reliability of the HP can be well accepted considering the uncertainties of quantitative Lu-177 imaging and BM dosimetry using standardised organ-level S values.\"}], \"pmcid\": \"PMC6081875\", \"doi\": \"10.1186/s13550-018-0427-z\"}\n", "stderr": ""}
{"seq": 21, "ts": "2026-02-20T10:31:03.325528+00:00", "agent": "agent3", "cmd": "pm audit", "exit_code": 0, "stdin_lines": 0, "stdout": "Audit Trail Summary\n===================\n\nTotal operations: 8\n\n  fetch            2\n  filter           2\n  init             1\n  search           3\n", "stderr": ""}
